AR052943A1 - Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida - Google Patents

Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida

Info

Publication number
AR052943A1
AR052943A1 ARP060100908A ARP060100908A AR052943A1 AR 052943 A1 AR052943 A1 AR 052943A1 AR P060100908 A ARP060100908 A AR P060100908A AR P060100908 A ARP060100908 A AR P060100908A AR 052943 A1 AR052943 A1 AR 052943A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
ring
group
alkyloxy
Prior art date
Application number
ARP060100908A
Other languages
English (en)
Inventor
Jeffrey Letourneau
Christopher Riviello
Koc-Kan Ho
Jui-Hsiang Chan
Michael Ohlmeyer
Patrick Jokiel
Irina Neagu
John Richard Morphy
Susan Elizabeth Napier
Original Assignee
Pharmacopeia Drug Discovery
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery, Organon Nv filed Critical Pharmacopeia Drug Discovery
Publication of AR052943A1 publication Critical patent/AR052943A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de 2-(4-oxo-4H-quinazolin-3-il)acetamida de la formula (1), donde: R1 es alquilo C1-6, cicloalquilo C3-6, cicloalquilC3-6alquiloC1-2, alquenilo C2-6, alquinilo C2-6, fenilo o bencilo, siendo dicho alquilo C1-6, cicloalquilo C3-6, y cicloalquilC3-6alquiloC1-2 opcionalmente sustituido con uno o más halogenos; R2 es un grupo seleccionado entre arilo C6-10 y cicloalquilo C4-7 o R2 es un sistema de anillo heteroarilo de 5 a 10 miembros comprendiendo un heteroátomo seleccionado de N, O y S; R3 es uno o dos sustituyentes seleccionados entre H, alquilo C1-6, alquiloxilo C1-6, y halogeno, estando dicho alquilo C1-6 y alquiloxilo C1-6 opcionalmente sustituido con uno o más halogenos; R4 es un grupo ubicado en la posicion 6 o 7 de un anillo de quinazolina, y es seleccionado del grupo de formulas (2), donde cada R5 es independientemente H o alquilo C1-6 o uno de R5 cuando está junto con uno de R6 o R7, forma un anillo heterocíclico de 5 a 6 miembros; R6 y R7 son independientemente H, alquilo C1-6, cicloalquilo C3-6, cicloalquilC3-6-alquiloC1-2, arilo C6-10 o arilC6-10alquiloC1-2; o R6 y R7 juntos con el nitrogeno al cual ellos están ligados, forman un anillo heterocíclico saturado o insaturado, de 4 a 8 miembros, comprendiendo opcionalmente otra mitad heteroatomica seleccionado de O, S y NR10, estando dicho anillo heterocíclico opcionalmente sustituido por uno o dos sustituyentes seleccionados entre halogeno, hidroxilo, alquilo C1-6, alquiloxilo C1- 6, ciano y COOR11 y estando dicho anillo heterocíclico opcionalmente fusionado con dos átomos de carbono adyacentes a un anillo de fenilo; o uno de R6 y R7, cuando están juntos con uno de R5 forman un anillo heerocíclico de 5 a 6 miembros; R8 es uno o dos sustituyentes seleccionados entre H, alquilo C1-6, alquiloxilo C1-6 y halogeno o uno de R8, cuando está junto con R9 forman un anillo de 5 a 6 miembros; R9 es H o alquilo C1-6 o R9, cuando está junto con uno de R8, forma un anillo de 5 a 6 miembros; R10 es H, alquilo C1-6 o acilo C1-6; R11 es H o alquilo C1-6; m es 2 a 4; n es 1 a 2; X es CH2, O, S, SO2 o NR12; R12 es H, grupo alquilo C1-6, acilo C1-6 o arilC6-10alquiloC1-2, estando dicho grupo arilC6-10alquiloC1-2 opcionalmente sustituido con metilo o metoxilo; Y es CH2, (CH2)2 o (CH2)3; Q, T, V y W son C o N con la condicion de que uno de Q, T, V y W es N y los otros son C; Q', T' y V' son seleccionados entre C, O, N y S con la condicion de que uno de Q', T' y V' es O, N o S y los otros son C; o una sal o solvato farmacéuticamente aceptable de ellos. Composiciones farmacéuticas que los contienen y usos como antidepresivos, siendo antagonistas del receptor V3 de vasopresina.
ARP060100908A 2005-03-11 2006-03-10 Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida AR052943A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66092605P 2005-03-11 2005-03-11
US71587505P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
AR052943A1 true AR052943A1 (es) 2007-04-11

Family

ID=36579595

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100908A AR052943A1 (es) 2005-03-11 2006-03-10 Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida

Country Status (18)

Country Link
US (1) US7807686B2 (es)
EP (1) EP1861380B1 (es)
JP (1) JP4997391B2 (es)
KR (1) KR20080009076A (es)
AR (1) AR052943A1 (es)
AT (1) ATE473214T1 (es)
AU (1) AU2006221962A1 (es)
CA (1) CA2599511C (es)
DE (1) DE602006015293D1 (es)
ES (1) ES2346790T3 (es)
IL (1) IL185343A0 (es)
MX (1) MX2007011023A (es)
NO (1) NO20074275L (es)
NZ (1) NZ560958A (es)
PE (1) PE20061106A1 (es)
RU (1) RU2007137649A (es)
TW (1) TW200643015A (es)
WO (1) WO2006095014A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
JP5271909B2 (ja) * 2006-09-11 2013-08-21 エム・エス・ディー・オス・ベー・フェー ２−（１−オキソ−１ｈ−イソキノリン−２−イル）アセトアミド誘導体
RU2009113612A (ru) * 2006-09-11 2010-10-20 Н.В. Органон (Nl) Ацетамидные производные хиназолинона и изохинолинона
CA2671891C (en) 2006-12-13 2015-05-26 N.V. Organon V3 antagonists for the treatment or prevention of chronic pain
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
JP5369721B2 (ja) * 2009-01-30 2013-12-18 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
WO2011091407A1 (en) * 2010-01-25 2011-07-28 Glaxosmithkline Llp Trpv4 antagonists
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
PT2621894T (pt) * 2010-09-27 2017-01-04 Du Pont Método para preparar 2-amino-n-(2,2,2-trifluoroetil)acetamida
TWI518075B (zh) 2010-10-01 2016-01-21 大正製藥股份有限公司 1,2,4-triazolone derivatives
BR112013028886A2 (pt) * 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
DK2772482T3 (en) 2011-10-27 2016-06-06 Taisho Pharmaceutical Co Ltd azole derivative
KR20140142244A (ko) * 2012-03-30 2014-12-11 다이쇼 세이야꾸 가부시끼가이샤 축환 아졸 유도체
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
MX2018000777A (es) * 2015-07-22 2018-03-23 Araxes Pharma Llc Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP7015059B2 (ja) 2015-11-16 2022-02-15 アラクセス ファーマ エルエルシー 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
EP3386591B1 (en) * 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
JP2020521742A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Ｋｒａｓの共有結合性阻害剤
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506767A1 (fr) * 1981-05-26 1982-12-03 Synthelabo Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique
FR2804114B1 (fr) * 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2842527B1 (fr) 2002-07-19 2005-01-28 Sanofi Synthelabo Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives

Also Published As

Publication number Publication date
US7807686B2 (en) 2010-10-05
NZ560958A (en) 2009-09-25
JP2008532981A (ja) 2008-08-21
EP1861380A1 (en) 2007-12-05
KR20080009076A (ko) 2008-01-24
CA2599511A1 (en) 2006-09-14
NO20074275L (no) 2007-09-27
PE20061106A1 (es) 2006-10-13
CA2599511C (en) 2013-12-10
AU2006221962A1 (en) 2006-09-14
MX2007011023A (es) 2008-03-12
TW200643015A (en) 2006-12-16
DE602006015293D1 (de) 2010-08-19
US20080214553A1 (en) 2008-09-04
WO2006095014A1 (en) 2006-09-14
ES2346790T3 (es) 2010-10-20
EP1861380B1 (en) 2010-07-07
RU2007137649A (ru) 2009-04-20
ATE473214T1 (de) 2010-07-15
IL185343A0 (en) 2008-02-09
JP4997391B2 (ja) 2012-08-08

Similar Documents

Publication Publication Date Title
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR062731A1 (es) Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion.
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR062937A1 (es) Compuestos que modulan el receptor cb2
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
AR047682A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR063147A1 (es) Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central.
AR062405A1 (es) Derivados de isoindol
PE20061362A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion
AR046992A1 (es) Derivados de espiro-dihidrobenzofuranos
AR062734A1 (es) Derivados de 2-(1-oxo-1h-isoquinolin-2-il)acetamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure